# US 2015/0147378 A1 · Copolymer-xerogel nanocomposites useful for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147378 A1
- Document ID: US20150147378A1
- Status: Published application
- Kind: A1
- Application number: 14/402,557
- Filed: 2013-05-21
- Published: 2015-05-28
- Earliest claimed: 2008-05-30
- Assignees: Rutgers, the State University of New Jersy; The Trustees of the University of Pennsylvania
- Applicants: Rutgers, the State University of New Jersy; The Trustees of the University of Pennsylvania
- Inventors: David Devore; Paul Ducheyne; Marius C. Costache
- Web page: https://patentgrep.com/patent/US20150147378A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61L 26/0004: {containing inorganic materials}
- A61L 26/0019: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/009: {Materials resorbable by the body}
- A61L 26/0095: {Composite materials, i.e. containing one material dispersed in a matrix of the same or different material}
- A61L 27/02: Inorganic materials
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/446: {with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/028: {Other inorganic materials not covered by A61L31/022 - A61L31/026}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/128: {containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/406: Antibiotics
- A61L 2300/604: Biodegradation
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Biocompatible, biodegradable copolymer-xerogel nanocomposites contain a biodegradable, biocompatible copolymer, silica nanoparticles and one or more therapeutic agents, that are useful for wound dressings, medical devices and drug delivery applications.

## Claims

### Claim 1

A copolymer-xerogel nanocomposite comprising:
a biodegradable, biocompatible copolymer;
silica nanoparticles; and,
therapeutic agent.

### Claim 2 (depends on 1)

The nanocomposite of claim 1, wherein the biodegradable, biocompatible copolymer has a molecular weight greater than 20,000 Daltons.

### Claim 3 (depends on 1)

The nanocomposite of claim 1, wherein said therapeutic agent is an antibiotic, a local anesthetic, and or a combination thereof.

### Claim 4 (depends on 1)

The nanocomposite of claim 1, wherein said therapeutic agent is rifampicin, bupivacaine, or both.

### Claim 5 (depends on 1)

The nanocomposite of claim 1, wherein said biodegradable copolymer comprises a copolymer of tyrosine-poly(alkylene glycol)-derived poly(ether carbonate).

### Claim 6 (depends on 5)

The nanocomposite of claim 5, wherein said biodegradable copolymer comprises a polycarbonate comprising desaminotyrosyl tyrosine ester and poly(ethylene glycol).

### Claim 7 (depends on 1)

The nanocomposite of claim 1, wherein the nanocomposite provides controlled release of said therapeutic agent.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

A drug depot, wound dressing, cardiovascular stent, or tissue scaffold comprising the nanocomposite of claim 1.

### Claim at position 10

-24. (canceled)

### Claim 25 (depends on 1)

The nanocomposite of claim 1, wherein the nanocomposite provides pseudo first-order release of said therapeutic agent.

### Claim 26 (depends on 1)

The nanocomposite of claim 1, wherein the silica nanoparticles have a diameter of no more than 50 nm.

### Claim 27 (depends on 1)

The nanocomposite of claim 1, wherein the copolymer contains the therapeutic agent.

### Claim 28 (depends on 27)

The nanocomposite of claim 27, wherein at least some of the silica nanoparticles contain the therapeutic agent.

### Claim 29 (depends on 1)

The nanocomposite of claim 1, wherein at least some of the silica nanoparticles contain the therapeutic agent.

### Claim 30 (depends on 1)

A method comprising applying to a subject or implanting within a subject a nanocomposite according to claim 1.
